Agenda: To review and evaluate grant applications.

Place: Crowne Plaza Washington National Airport, 1489 Jefferson Davis Hwy, Arlington, VA 22202.

Contact Person: Ryan G Morris, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4205, MSC 7814, Bethesda, MD 20892, 301–435–1501, *morrisr@csr.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: September 14, 2015.

Melanie J. Gray,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2015–23387 Filed 9–17–15; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Neurological Disorders and Stroke; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Muscular Dystrophy Coordinating Committee (MDCC).

The meeting will be open to the public and accessible by live webcast.

Name of Committee: Muscular Dystrophy Coordinating Committee.

Type of meeting: Open Meeting.

Date: November 13, 2015.

Time: 8:30 a.m. to 4:30 p.m. *Eastern Time*—Approximate end time.

Agenda: The purpose of this meeting is to bring together committee members, representing government agencies, patient advocacy groups, other voluntary health organizations, and patients and their families to update one another on progress relevant to the Action Plan for the Muscular Dystrophies and to coordinate activities and discuss gaps and opportunities leading to better understanding of the muscular dystrophies, advances in treatments, and reduced disease burden. Prior to the meeting, an agenda will be posted to the MDCC meeting registration Web site: *https://meetings.ninds.nih.gov/meetings/MDCC13Nov2015/.*

Registration: To register, please go to: *https://meetings.ninds.nih.gov/meetings/MDCC13Nov2015/.*

Webcast Live: For those not able to attend in person, this meeting will be webcast at: *http://videocast.nih.gov/.*

Place: Neuroscience Center, Conference Room C/D, 6001 Executive Boulevard, Rockville, Maryland 20852.

Contact Person: Glen H. Nuckolls, Ph.D., Executive Secretary, Muscular Dystrophy Coordinating Committee, National Institute of Neurological Disorders and Stroke, NIH, 6001 Executive Boulevard, NSC 2203, Rockville, MD 20852, (301) 496–5739, *glen.nuckolls@ninds.nih.gov.*

Any member of the public interested in presenting oral comments to the committee may notify the Contact Person listed on this notice at least 10 days in advance of the meeting. Interested individuals and representatives of organizations may submit a letter of intent, a brief description of the organization represented, and a short description of the oral presentation. Only one representative of an organization may be allowed to present oral comments and if accepted by the committee, presentations may be limited to five minutes. Both printed and electronic copies are requested for the record. In addition, any interested person may file written comments with the committee by forwarding their statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Attendance is limited to seating space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should inform the Contact Person listed above in advance of the meeting. All visitors must go through a security check at the meeting site to receive a visitor's badge. A valid, government issued photo ID must be presented before a visitor's badge can be issued. Further information can be found at the registration Web site: *https://meetings.ninds.nih.gov/meetings/MDCC13Nov2015/.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)

Dated: September 14, 2015.

Carolyn Baum,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2015–23443 Filed 9–17–15; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

In Vitro to In Vivo Extrapolation for High Throughput Prioritization and Decision Making; Notice of Webinars and Public Workshop; Registration Information

SUMMARY: The National Toxicology Program (NTP) Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) and the U.S. Environmental Protection Agency (EPA) announce the workshop, ''*In Vitro* to *In Vivo* Extrapolation for High Throughput Prioritization and Decision Making.'' Attendees at the in-person workshop and four webinar presentations leading up to the workshop will discuss the state of the science and best practices for using *in vitro* to *in vivo* extrapolation (IVIVE) in a tiered risk decision context.

DATES: *Webinars:* October 7, 2015, at 11:00 a.m. Eastern Daylight Time (EDT); and November 4, 2015; December 2, 2015; and January 6, 2016; at 11:00 a.m. Eastern Standard Time (EST).

Webinar Registration: Deadline is two business days prior to each webinar.

Workshop: February 17–18, 2016, from 9:00 a.m. to approximately 5:00 p.m. (EST).

Workshop Registration: Deadline is February 5, 2016 at 5:00 p.m. (EST).

ADDRESSES:

Workshop Location: U.S. Environmental Protection Agency, 109 T.W. Alexander Dr., Durham, NC, 27709.

Web page: The preliminary agenda, registration, and other meeting materials will be available at *http://ntp.niehs.nih.gov/go/ivive-wksp-2016.*

FOR FURTHER INFORMATION CONTACT: Dr. Warren S. Casey, Director, NICEATM; email: *warren.casey@nih.gov;* telephone: (919) 316–4729.

SUPPLEMENTARY INFORMATION:

Background: Data from high throughput *in vitro* tests are being generated for many chemicals of environmental and commercial interest, with the expectation that *in vitro* assay data could ultimately be used to predict adverse effects of chemical exposures *in vivo.* Translating values obtained from *in vitro* assays into estimates of *in vivo* outcomes is a complex process involving the use of mathematical modeling and increasingly complex test systems. The series of four webinars and in-person workshop aim to address the capabilities and limitations of IVIVE within the context of risk decision-making.

The webinar series will present the current science, and the in-person workshop will facilitate discussions that follow-up and build on information presented in the webinars. During the workshop, participants will (1) review the state of the science to form recommendations on best practices for using IVIVE in chemical screening and risk-based decision making, (2) identify areas that require additional data and/or research, and (3) highlight examples of how best to apply IVIVE in a tiered risk decision-making strategy.

Preliminary Agenda and Other Meeting Information: A preliminary agenda and additional information will